Lantern Pharma Inc. Q3 FY2024 earnings call

• AI-driven clinical progress: Three precision oncology drug candidates in clinical trials guided by RADR AI platform, including Phase I and II programs. Preclinical ADC candidates also in development. • Harmonic trial: LP-300 shows 86% clinical benefit rate in first seven patients; expanding to Asia (Japan and Taiwan) with 10 sites. • LP-184 and LP-284: Phase Ia trials with over 50 patients dosed, no dose-limiting toxicities; FDA designations received. • R&D updates: Scientific publications, exploration of combination regimens for LP-184 (e.g., with PARP inhibitors, spironolactone, immune checkpoint inhibitors). • Starlight Therapeutics: Launch of CNS subsidiary, Scientific Advisory Board with preeminent neuro oncology experts, plans for early 2025 trials. • Financials: Solid cash position providing runway into late 2025, focus on Radar AI platform development and portfolio of oncology drug candidates.

No detailed product segment financial performance with revenue contribution percentages provided in the transcript. Financial highlights include a net loss of approximately $4.5 million for Q3 2024, R&D expenses of approximately $3.7 million (up from $2.2 million in Q3 2023), G&A expenses of approximately $1.5 million (up slightly from Q3 2023), cash position of approximately $28.1 million as of September 30, 2024, and 10,784,725 shares of common stock outstanding with fully diluted shares at ~12.1 million.

• Cash runway: Believes cash position of ~$28.1 million provides runway into at least late 2025. • Development: Anticipates continued development of Radar AI platform, portfolio of targeted oncology drug candidates, and introduction of additional targeted programs and collaboration opportunities. • Clinical trials: Expect to leverage internal clinical operations capabilities across trials, making efficient use of capital.

• Forward-looking statements subject to risks such as results of clinical trials, impact of competition. • Factors causing actual results to differ materially from forward-looking statements include those in the annual report on Form 10-K for the year ended December 31, 2023, available on the SEC and company website.

Q: When do we expect additional data regarding our HARMONIC and LP-300 trial?

A: Goal is to gather another 14 to 28 patients actively. Interim analysis at 31 patients, with next big clinical readout expected around mid-next year.

Q: Any updates on how Radar is growing and collaboration efforts?

A: Collaboration with Oregon Therapeutics progressing, expected to finalize first phase by end of year; now focusing on larger biotech companies.

Q: Can we speak to any partnership interest?

A: Early discussions in Asia regarding partnership, licensing, or co-development of LP-300 in that geography; interest from pharma companies due to prevalence of disease in East Asia.

Q: On Starlight Therapeutics and the Scientific Advisory Board members?

A: Thrilled about Scientific Advisory Board members (DeAngelis, Berger, Latera, Grossman); progress in opening sites, enrolling patients, with plans for trials in early 2025; considering best route to capitalize Starlight independently.